

Initials: HEW/RHU/sl Docket No.: 1855.1064-003 Date: 3/5/2004

This is to acknowledge receipt of the following documents each filed under Certificate of Mailing Procedure 37 C.F.R. 1.8:

- Amendment/Reply Fee Letter w/copy Pet Ext Time w/copy
 AMENDMENT
 AMENDMENT AFTER FINAL ACTION
 Copy of Executed Declaration Under 37 C.F.R. § 1.131 w/Exhibit (3 docs, 12 pages)
 Check for \$ 950 _____ Auth to charge fees
 REPLY TO OFFICE ACTION
 Other Exhibit A The Journal of Immunology Posting Dates (pp. 1-9)

Applicant: David P. Andrew *et al.*


Application No.: 09/522,752

Filed: March 10, 2000

Title: METHODS OF INHIBITING GPR-9-6 FUNCTION (As Amended)

MAR 3 6 2004

Date received by the PTO:



COPY

@PFDdesktop:ODMA/MHODMA/FBSR05\Manage;451525.1
HEW/RHU
February 23, 2004

PATENT APPLICATION
Attorney's Docket No.: 1855.1064-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath

Application No.: 09/522,752 Group: 1644

Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.

Confirmation No.: 4952

For: METHODS OF INHIBITING GPR-9-6 FUNCTION

| | |
|--|-----------------------------------|
| CERTIFICATE OF MAILING OR TRANSMISSION | |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage in First Class Mail in an envelope addressed to Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, or is being electronically submitted to the United States Patent and Trademark Office on | |
| March 5, 2001 | <i>Shannon L. S.</i> Signature |
| Shannon L. S. Typed or printed name of person signing certificate | |

DECLARATION UNDER 37 C.F.R. § 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

COPY

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.E.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

COPY

09/522,752

-3-

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

D.P. Andrew

David P. Andrew Ph.D.

March 2 2004

Date

Brian A. Zabel

Date

Paul D. Ponath, Ph.D.

Date

COPY

Aug-05-04 04:08pm From-HBSR

104

Book No.


TITLE L1.2_GPRG6 General Screen

1-978-341-0242

T-984 P 21/29 F-615


From Page No.

GPR2 0501 489
GPR3 0501 341 ① 503
GPR4 1750 506
GPR5 6487
GPR6 2200
GPR7 1600
JOHN TECK 3C3 49
GPR2 5707 503
GPR5 6048
SVR6 1443
GPR1 417
GPR2 0501 503



Chemicals

GPR2 0501 489/503 ① 503
GPR1 2 210
GPR2 2 20/275 220/53
GPR3 6 709 1037 557 719
GPR4 3C3 120 51 418
GPR5 1025 1207 114 127
GPR6 1160 1047 103 52
GPR7 1032 106 1023 11
GPR8 1124 863 1031 237
GPR9 0 4 2/3



To Page No.

Assed & Understood by me,

Date

Invented by

Date

J. Mehta

COPY

Recorded by

R. A.

EXHIBIT

@PFDekop:ODMA/MHODMA/HBSR05,Manage;451325,1
HEW/RHU
February 23, 2004

PATENT APPLICATION
Attorney's Docket No. 1655.1064-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath

Application No.: 09/522,752 Group: 1644

Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.

Confirmation No.: 4952

For: METHODS OF INHIBITING GPR-9-6 FUNCTION

| | |
|--|-------------------------|
| CERTIFICATE OF MAILING OR TRANSMISSION | |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being transmitted electronically to the United States Patent and Trademark Office on. | |
| <i>2/23/04</i> | <i>Jessica H. Roark</i> |
| Date | Signature |
| <i>Jessica H. Roark</i> | |
| Typed or printed name of person signing certificate | |

DECLARATION UNDER 37 C.F.R. § 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

COPY

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.E.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

COPY

09/522,752

-3-

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

David P. Andrew Ph.D.

Date

Brian A. Zabel

2-26-04

Brian A. Zabel

Date

Paul D. Ponath, Ph.D.

Date

COPY

Aug-05-04 04:09pm From-HBSR

1-978-341-0242

T-984 P.25/29 F-615


Book No.

TITLE L.2 GPR26 General Screen

64


From Page No. -

| | | | |
|-----------|--------|--------|-----|
| - | GPR2 | 05.5ml | 489 |
| - | 3P23 | 05.5ml | 341 |
| - | GPR2 | 1750 | 894 |
| - | GPR5 | 6457 | 1 |
| - | GPR6 | 22.08 | 1 |
| - | GPR1 | 21666 | ↓ |
| Cult TECR | 2C3 | 49 | |
| | 3P2 | 5.5ml | 123 |
| | 3P45 | 6048 | |
| | 3P6 | 1443 | |
| | 5P11 | 419 | |
| | 5P2054 | 503 | |



Chemicals

| | | | | |
|---|------|------|-----------|----|
| 1 | GPR2 | 10 | 489 / 503 | 02 |
| 2 | GCR1 | 2 2 | 2110 | |
| 2 | P3H | 275 | 320 / 63 | |
| 3 | G13 | 7.5 | 659 / 72 | |
| 4 | 707 | 1037 | 873 / 231 | |
| 5 | 3.2 | 20 | 4 / 2 | |
| | 1025 | 1264 | 114 / 122 | |
| 3 | 3P25 | 1180 | 102 / 52 | |
| 4 | 1P27 | 104 | 102 / 14 | |
| 6 | 6G4 | 1179 | 103 / 237 | |
| - | 0 | 4 | 2 / 3 | |



To Page No. .

Signed & Understood by me,

Date

Invented by

*J. Michael***COPY**

Recorded by

D. A.

Date

EXHIBIT

@PFDelstop\ODMA\MHODMA\HBSR05\Manage,451325;1
HEW/RHU
February 23, 2004

PATENT APPLICATION
Attorney's Docket No. 1855.1064-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David P. Andrew, Brian A. Zabel and Paul D. Ponath

Application No.: 09/522,752 Group: 1644

Filed: March 10, 2000 Examiner: Jessica H. Roark, Ph.D.

Confirmation No.: 4952

For: METHODS OF INHIBITING GPR-9-6 FUNCTION

| | |
|--|-----------|
| CERTIFICATE OF MAILING OR TRANSMISSION | |
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P O Box 1450, Alexandria, VA 223-3-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on. | |
| March 5, 2004 | Signature |
| Shawn L. Lin | |
| Typed or printed name of person signing certificate | |

DECLARATION UNDER 37 C.F.R. § 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, David P. Andrew, Brian A. Zabel and Paul D. Ponath, hereby declare and state:

COPY

09/522,752

-2-

1. We produced monoclonal antibody GPR96-1 (mAb GPR96-1) in the United States, and were in possession of the invention claimed in the subject application, before May 11, 1999.
2. Evidence is provided in the Exhibit, which is a copy of page 164 of a notebook maintained by inventor David P. Andrew. In accordance with accepted practice, the dates on the copy of the notebook page are masked. (M.P.E.P. § 715.07) In the original notebook, page 164 bears a date of recordation prior to May 11, 1999.
3. A manuscript table and a histogram are presented on the bottom half of the Exhibit, which describe the results of a study demonstrating that mAb 3C3 and mAb GPR96-1 inhibited TECK-induced chemotaxis of transfected L1.2 cells that expressed a recombinant human GPR-9-6. The ability of mAb GPR96-1, mAb GPR96-2, mAb GPR96-3, mAb GPR96-5, mAb 3C3, mAb 3B8, mAb 42C and mAb 6G4 to inhibit TECK-induced chemotaxis was evaluated in duplicate wells. Control wells contained no TECK (results presented at top of histogram (-)), or TECK but not antibody (results presented in center of histogram between 3B8 and 3C3 (-)). The manuscript table includes the antibody tested, the number of cells that migrated to the bottom chamber in each well, the average number of cells that migrated and the standard deviation. The results are presented graphically in the histogram, and show that mAb 3C3 and mAb GPR96-1 each inhibited TECK-induced chemotaxis of cells expressing a recombinant human GPR-9-6.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

COPY

09/522,752

-3-


Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

David P. Andrew Ph.D.

Date

Brian A. Zabel

Date


Paul D. Ponath, Ph.D.

Date

02.25.04

COPY

164

Book No.



TITLE L1.2 GPR06 General Screen

From Page No.

| | | |
|-----------|------|-------|
| SP2 | 05ml | 489 |
| 3C3 | 05ml | 341 |
| Gp12 | | 105ml |
| Gp15 | | 4750 |
| Gp6 | | 5467 |
| Gp1 | | 2200 |
| Gp1 | | 21600 |
| 10m TECOK | BC3 | 49 |
| 302 | | 572 |
| 325 | | 6048 |
| 306 | | 144B |
| SP1 | | 419 |
| SP205ml | | 503 |

Chemicals

| | | | | |
|-----|------|------|-----|----------|
| SP2 | 0d | 489 | 503 | 100 |
| Gp1 | | 22 | | 210 |
| 2 | 264 | 275 | | 320/63 |
| 3 | 613 | 705 | | 669, 74 |
| 2 | 704 | 1032 | | 873/231 |
| 3c3 | 20 | 5 | | 1718 |
| | 1624 | 1207 | | 1114/127 |
| 325 | 110 | 1044 | | 102/52 |
| 4C | 105 | 101 | | 1023/116 |
| Gp1 | 1124 | 853 | | 1031/237 |
| | 0 | 4 | | 3/3 |



To Page No.

Signed & Understood by me,

Date

Invented by

Date

*D-A**D-A**Same date***COPY**

Recorded by

